Abstract Since the discovery over 60 years ago of fluorocortisone's biological properties (9-α-Fluoro derivatives of cortisone and hydrocortisone; Fried J and Sabo EF, J Am Chem Soc 76: [1455][1456] 1954), the number of fluorinated drugs has steadily increased. With the improvement in synthetic methodologies, this trend is likely to continue and will lead to the introduction of new fluorinated substituents into pharmaceutical compounds. Although the biotransformation of organofluorine compounds by microorganisms has been well studied, specific investigations on fluorinated drugs are relatively few, despite the increase in the number and variety of fluorinated drugs that are available. The strength of the carbon-fluorine bond conveys stability to fluorinated drugs; thus, they are likely to be recalcitrant in the environment or may be partially metabolized to a more toxic metabolite. This review examines the research done on microbial biotransformation and biodegradation of fluorinated drugs and highlights the importance of understanding how microorganisms interact with this class of compound from environmental, clinical and biotechnological perspectives.
Introduction
Approximately 25 % of drugs, either currently available or in the pipeline, are fluorinated, and typically contain fluorophenyl or trifluromethylphenyl groups (Fig. 1) . Six new fluorinated drugs were approved by the FDA in 2014 (Jarvis 2015) , and it is expected that the number of fluorinated drugs will increase year-on-year. Fluorine's unique physicochemical properties, in particular the van der Waals radius (1.35 Å), which is between that of hydrogen (1.20 Å) and the oxygen of hydroxyl (1.40 Å), electronegativity and stability of the C-F bond can enhance certain properties of drugs such as lipophilicity, metabolic stability, and potency (Murphy and Sandford 2015) . While regio-and stereo-selective fluorinations are chemically challenging, synthetic methodologies have been developed that enable fluorination of a wide variety of druglike molecules and building blocks. Enzymatic methods are now part of the toolbox to enable specific fluorination of pharmaceutically relevant molecules; for example, the fluorinase from Streptomyces cattleya can be used to incorporate radioactive F-18 into molecules that can be employed in positron emission tomography (PET) (Onega et al. 2010; Rentmeister et al. 2009 ) combined cytochrome P450 hydroxylation and deoxofluorination with DAST (diethyl aminoethyl trifluoride) to produce fluorinated ibuprofen. The continued and increasing use of fluorine in drug manufacture has implications for the environment that urgently require attention.
In addition to pharmaceuticals, fluorine is used in the manufacture of agrochemicals and industrial chemicals such as aerosols and refrigerants; naturally produced organofluorines are rare (O'Hagan and Deng 2015) .
Consequently, anthropogenic fluorinated compounds are commonly found in the environment. While some can be readily degraded, others, in particular perfluorinated compounds, are recalcitrant and accumulate in the environment. PFOA (perfluoro-octanoic acid), for example, is used in the preparation of fluoropolymers and has been detected in the bloodstream of humans and animals (Fromme et al. 2009 ). Chronic exposure to high concentrations of this compound in animals results in increased incidence of tumors (Biegel et al. 2001) . Thus, such compounds are an environmental and health concern.
Pharmaceutical compounds and their metabolites have been detected in sewage and their removal rates are a focus of current research efforts (Gurke et al. 2015) . Fluorinated compounds are a significant subset of pharmaceuticals and contamination of the environment by such compounds, in particular fluoroquinolone antibiotics, is worthy of separate study. Microorganisms can degrade myriad xenobiotic compounds, including those that are fluorinated, thus, have the potential to bioremediate contaminated environments containing fluorinated pharmaceuticals. In this paper, the bacterial and fungal biotransformation of fluorinated drugs will be reviewed and the possible applications discussed.
Monitoring fluorinated drug biotransformation
A convenient technique for assessing the biotransformation of fluorinated compounds is fluorine-19 nuclear magnetic resonance spectroscopy , which enables the observation of newly formed fluorometabolites without the need for purification. The sensitivity of F-19 NMR is comparable to that of H-1 NMR; thus, μM concentrations of compounds can be detected, and even minor structural modifications to will lead to significant chemical shift changes. Corcoran et al. (2001) demonstrated that F-19 NMR was an effective tool for screening fluorinated drug metabolism. The biotransformation of three fluorinated drug-like compounds by 48 microbial strains was assessed by cultivating the microorganisms in 24-well plates, incubating with the fluoro-drug (1 mM) for 10 days before quenching with acetonitrile:water (4:1) and recording the F-19 NMR spectra of the culture supernatants.
While the technique has been applied in the study of microbial biotransformation of other fluorinated drugs, limited structural information regarding the products is provided; thus, other techniques, such as HPLC, GC-and LC-MS, and ion selective electrodes, are often applied in conjunction with F-19 NMR. Qin et al. (2012) developed a LC-continuum source molecular absorption spectrometry (CS-MAS)
Zontivity (reduces risk of heart attack/stroke) Fig. 1 Examples of fluorinated drugs technique that can be applied to fluorinated compounds and has a detection limit in the nM range, thus, is highly applicable for environmentally relevant fluorinated drugs and their metabolites.
Overview of microbial biotransformation of organofluorine compounds
Bacteria and fungi are known to transform and degrade model aromatic and aliphatic organofluorine compounds, and this topic has been thoroughly reviewed recently (Kiel and Engesser 2015) . While the focus of the current review is on fluorinated drugs, many of the biochemical pathways revealed through the study of model organofluorine compounds are relevant; thus, a brief summary of the key findings is given below. For mineralization of organofluorine compounds, cleavage of the highly stable C-F bond is necessary. This can be achieved either directly via the actions of a specific dehalogenase enzyme or indirectly as a consequence of the formation of an unstable metabolic intermediate. Fluoroacetate dehalogenase is the only class of enzyme known to specifically hydrolyse C-F, yielding fluoride ion and glycolate, and the enzyme has been isolated from a number of bacterial species (Goldman 1965; Kurihara et al. 2003; Donnelly and Murphy 2009 ). In addition to being used as a rodenticide in some countries, fluoroacetate is the most abundant naturally produced organofluorine compound (O'Hagan and Deng 2015); thus, microorganisms have evolved to employ this compound as a carbon and energy source (Camboim et al. 2012) .
A r o m a t i c co m po u nd s s uc h a s f l uo r op h e no l s , fluorobenzene, and fluorobenzoic acids can be biotransformed by microorganisms through the established catabolic pathways (Boersma et al. 2004; Carvalho et al. 2008; Kim et al. 2010; Duque et al. 2012) . The oxygenase enzymes that are involved in these pathways in aerobic microbes will accept fluorinated derivatives of their natural substrates, owing to the limited steric impact of the small fluorine atom. Depending on the position of the fluorine, formation of the oxidized intermediates can result in the spontaneous elimination of fluoride ion or formation of a dead-end fluorometabolite (Harper and Blakley 1971; Clarke et al. 1975; Schreiber et al. 1980; Engesser et al. 1990 ). For example, 3-fluorobenzoic acid is a sole carbon and energy source for Sphingomonas sp. HB1 and is catabolized via the benzoate-degrading pathway (Boersma et al. 2004 ). The first enzyme of this pathway, benzoate dioxygenase, hydroxylates the substrate at either C-1/C-2 or C1/C6, yielding both 3-fluoro-and 5-fluoro-fluorocyclohexadiene cis,cis-1,2-diol-1-carboxylate, which are respectively transformed to 3-and 4-fluorocatechol (Fig. 2) . The latter is completely degraded releasing fluoride ion, but 3-fluorocatechol is catabolized to the dead-end metabolite 2-fluoro-cis,cis-muconic acid. Most other reports of fluoroaromatic biodegradation via 3-fluorocatechol observe the same accumulation of the fluorinated muconate. However, a notable exception is Burkholderia fungorum FLU100, which mineralises fluorobenzene principally via 3-fluorocatechol and 2-fluorocis,cis-muconic acid, yielding fluoride ion (Strunk and Engesser 2013) .
The biodegradation of trifluoromethyl-substituted aromatic compounds is less well studied, yet the trifluoromethyl phenyl group is present in a large number of drugs, including the blockbuster selective serotonin reuptake inhibitor Prozac (fluoxetine) and the COX-2 inhibitor celecoxib. Engesser et al. (1988a, b) studied the co-metabolism of 3-and 4-trifluoromethyl benzoates in Pseudomonas putida strains and observed limited biodegradation and the accumulation of 2-hydroxy-6-oxo-7,7,7-trifluorohepta-2,4-dienoate (7-TFHOD, Fig. 3 ). In a separate study with a marine bacterium, Taylor et al. (1993) trifluoromethylbenzoates via a combination of biodegradation to 7-TFHOD and photodegradation. The thermophilic bacterium Bacillus thermolevorans biotransformed 2-trifluoromethylphenol to 7-TFHOD, and by F-19 NMR, it was possible to observe that the isolated metabolite was degraded by sunlight. However, no fluoride ion was detected, and it was reasoned that the photoexcited molecule was a trifluoromethyl radical that abstracted a proton from water yielding volatile fluoroform that was readily lost to the atmosphere. Yano et al. (2015) isolated a bacterial strain, Rhodococcus sp. 065240, that degrades benzotrifluoride yielding trifluoroacetic acid. A gene cluster (btf) was identified as being necessary for the biodegradation, and sequence analysis revealed homology with the ipb cluster enabling isopropylbenzene biodegradation in Rhodococcus erythropolis BD2.
Fluoroquinolone antibiotics
Fluoroquinolone antibiotics (Fig. 4) , such as ciprofloxacin and norfloxacin, are important human and veterinary drugs widely used in the treatment of serious bacterial infections. Quinolone antibiotics inhibit DNA synthesis targeting both DNA gyrase and topoisomerase IV. Of a major concern is the development of resistance to these antibiotics, and the extensive use of fluoroquinolones results in many microorganisms in the wider environment coming into contact with them. Understanding microbial biotransformation of these drugs is crucial in predicting the likely mechanism of resistance. Kim et al. (2011) were first to isolate a bacterium that could biotransform a fluoroquinolone antibiotic. Using wastewater as an inoculum and N-phenylpiperazine as a carbon source, a Microbacterium sp. was enriched that was insensitive to norfloxacin. The bacterium could not grow on norfloxacin, but biotransformed it to four metabolites: 8-hydroxynorfloxacin, 6-defluoro-6-hydroxynorfloxacin, desethylene norfloxacin, and N-acetylnorfloxacin (Fig. 5) . The latter required the presence of casamino acids in the medium, and a glutamine synthase was subsequently isolated that catalyzed this reaction (Kim et al. 2013) . The production of the hydroxylated metabolites was inhibited by free radical scavengers; thus, it was inferred that these metabolites were formed from hydroxyl radicals.
The bacterium Labrys portucalensis F11, which was originally isolated by enrichment on fluorobenzene as a sole carbon and energy source, can co-metabolize fluoroquinolone antibiotics (Amorim et al. 2014) . While the antibiotic effects of ciprofloxacin, norfloxacin, and ofloxacin were observed at concentrations above 3.5 μM, the bacterium could transform all three of the fluoroquinolones, either separately or as a mixture. Complete defluorination was not observed, but reached approx. 60 % for ofloxacin (2 μM) when incubated with cells supplemented with 5.9 mM acetate. Detection of metabolites was afforded by LC-MS and indicated several biotransformation reactions that were similar to those reported in Microbacterium N2-2 (Kim et al. 2011 ) and included hydroxylation/defluorination, demethylation, decarboxylation, and piperzine ring cleavage.
Fungal biotransformation of fluoroquinolones has been studied in a number of species (Table 1) . Mineralisation of the antibiotics, as determined by measuring 14 CO 2 emissions from radiolabeled starting material, was observed in some basidiomycetes (Wetzstein et al. 1999; Marengo et al. 2001) . Numerous metabolites have been identified, most notably from Gloeophyllum striatum, which are thought to arise through reaction with extracellularly generated hydroxyl radicals produced by lignin-degrading enzymes (Karl et al. 2006) . Commonly detected transformations reported are similar to those observed in bacteria and include modification of the piperazinyl ring (deethylation, N-acetylation, Ni ii 2-hydroxy-6-oxo-7,7,7-trifluorohepta-2,4-dienoate (7-TFHOD) 3-trifluoromethyl benzoic acid Fig. 3 Biotransformation of trifluoromethylbenzoic acid by Ps. putida via benzoate dioxygenase (i) and catechol 2,3-dioxygenase (ii) yielding the metabolite 7-TFHOD Fig. 4 The general structure of fluoroquinolone antibiotics formylation), decarboxylation, and hydroxylation. Wetzstein et al. (2012) demonstrated for the first time the formation of a catechol-type metabolite from pradofloxacin, and a late-stage ring-opened metabolite (Fig. 6) , suggesting a mechanism for complete degradation of this class of antibiotic. Despite the extensive effort in determining the intermediates arising from microbial biotransformation of fluoroquinolone antibiotics, little is known about the enzymes involved. In some fluoroquinolone-resistant bacteria, an N-acetyl transferase can biotransform the antibiotics, thereby eliminating bioactivity (Adjei et al. 2006; Jung et al. 2009 ). The biotransformation of flumequine to diastereomers of 7-hydroxyflumequine in Cunninghamella elegans (Williams et al. 2007 ) is likely to be catalyzed by cytochrome P450. Prieto et al. (2011) demonstrated that laccase degraded Irpex lacteus X X X C v a n c a r o v ae ta l .2015 Pleurotus ostreatus X X X C v a n c a r o v ae ta l .2015
Trametes versicolor X X X C v a n c a r o v ae ta l . ciprofloxacin in vitro and inferred from inhibitor studies that cytochrome P450 is also involved in the biodegradation of fluoroquinolone antibiotics in Trametes versicolor. Cvancarova et al. (2015) conducted Principle Component Analysis of the ligninolyitc enzyme activities (laccase, manganese peroxidase, and manganese independent peroxidase) of several fungi in the presence of ciprofloxacin, norfloxacin, and ofloxacin. Manganese peroxidase correlated with the degradation of the three antibiotics, suggesting a role for this enzyme in the degradation process.
Antidepressants
Fluoxetine (Prozac) is a widely prescribed antidepressant that contains a trifluoromethylphenyl moiety (Fig. 7) . It is recalcitrant and has been detected in waterways where it exerts measureable biological effects on the aquatic animals (Silva et al. 2015) . Rodarte-Morales et al. (2011) studied the degradation of fluoxetine and another fluorinated antidepressant, citalopram (Fig. 7) by three white-rot fungi: an anamorph of Bjerkandera sp. R1, Bjerkandera adjusta and Phanerochaete chrysosporium. While citalopram (1 mg/l) was completely degraded by all three species after 14 days, fluoxetine was comparatively poorly degraded, to a maximum of 46 % in culture of the anamorph of Bjerkandera sp. R1. No intermediates were determined in the study, and although MnP activity was measured, no in vitro experiments with the enzyme were reported.
The bacterium L. portucalensis F11 can degrade fluoxetine, releasing stoichiometric amounts of fluoride ion from low concentrations (2 μM) of substrate . In the presence of another, more readily useable carbon source, such as acetate, higher concentrations of fluoxetine could be degraded. Furthermore, the authors demonstrated that the R-enantiomer was preferentially degraded by the bacterium. No intermediates were detected, which is frustrating s i n c e m i n e r a l i z a t i o n o f c o m p o u n d s c o n t a i n i n g trifluoromethylphenyl via biotransformation is very rare. Nevertheless, this bacterium might enable further understanding of the metabolism and enzymology of xenobiotics containing trifluoromethyl-substituted aromatic systems.
Flurbiprofen
Biphenyl structures are common in pharmaceuticals and microbial degradation of this moiety is known. Biotransformation of fluorinated biphenyls to hydroxylated products has been reported in fungi (Green et al. 1999; , although full biodegradation has not been observed. The b i p h e n y l -d e g r a d i n g b a c t e r i u m P s e u d o m o n a s pseudoalcaligenes KF707 can grow on mono-, di-, and polyfluorinated biphenyls (Murphy et al. 2008; Hughes et al. 2011) , employing the upper biphenyl-degrading pathway.
The fluorobiphenyl-containing drug flurbiprofen can be biotransformed to various oxidized fluorometabolites (Fig. 8) by fungi belonging to the genus Cunninghamella and Streptomyces bacteria Bright et al. 2011) . These organisms are producers of cytochromes P450 and are established models of mammalian xenobiotic metabolism (Murphy 2015) . E. coli expressing cyanobacterial cytochrome P450 (CYP110E1) transformed flurbiprofen methyl ester into two hydroxylated products at very low (<5 %) yield (Makino et al. 2012) . Such biotransformations can be useful in identifying metabolically labile sites on drug molecules so that more stable/potent derivatives can be prepared (Shaughnessy et al. 2014) . Racemic flurbiprofen can be resolved by incubation of the compound with dried mycelium of Aspergillus oryzae suspended in an organic solvent (e.g. toluene) with ethanol (Spizzo et al. 2007 ). The fungus enantioselectively esterifies R-flurbiprofen. (Fig. 9) is a widely used nonsteroidal, antiandrogen drug for the treatment of prostate cancer. In vivo it is extensively transformed to bioactive metabolites, notably 2-hydroxyflutamide and 4-nitro-3-(trifluoromethyl) phenylalanine. Two studies have examined the microbial biotransformation of this drug. Herath and Khan (2010) screened 40 microorganisms for the ability to transform flutamide and observed the fungi Rhodotorula mucilaginosa (ATCC 20129) and Beauveria bassiana (ATCC 7159) and the bacterium Nocardia sp.
(NRRL 5646) produced three metabolites via hydrolysis of the isobutanoyl group, nitroreduction and N-acetylation (Table 2 ). In a second study Amadio and Murphy (2011) demonstrated the production of hydroxylated metabolites from flutamide incubated with C. elegans, which has the necessary cytochrome P450 activity to catalyze such biotransformations. When the drug was incubated with biofilms of C. elegans, a substantial decrease in biomass was observed strongly suggesting that the compound is highly toxic and may be concentrated in the biofilm (Quinn et al. 2015) , which has implications in the wider environment where biofilms are the dominant mode of growth of microorganisms.
Fluorouracil 5-Fluorouracil (5FU) is a very common anticancer compound first introduced in the 1950s and is detected in hospital and municipal wastewaters (Kosjek et al. 2013) . Its biodegradation has not been well studied, although Lutterbeck et al. (2015) demonstrated that in closed bottle tests, using the final effluent from a municipal sewage treatment plant as an inoculum, 5FU was not biodegraded over 28 days. However, in the same study biodegradation of transformation products arising from UV/H 2 O 2 treatment of 5FU could be inferred from Biochemical Oxygen Demand measurements.
Atorvastatin
The cholesterol-lowering drug atorvastatin (Fig 1) is one of the best selling drugs of all time. Despite its wide use, studies on its biodegradation are few. No studies on the bacterial degradation of this compound are reported, but Rodríguez-Rodríguez et al. (2011 have studied the application of the white-rot fungus T. versicolor for pharmaceutical removal, including atorvastatin. They reported a reduction from 38 to 5 ng/g atorvastatin when the fungus was grown on sterile sewage sludge for 42 days (Rodríguez-Rodríguez et al. 2011) . A similar reduction was observed when nonsterile sludge was augmented with the fungus (Rodríguez-Rodríguez et al. 2012) . Laccase activity was proposed as a significant factor in the biodegradation of the pharmaceuticals, although no in vitro experiments were conducted. No analysis of the metabolites was conducted, but the toxicity of the treated sludge was significantly reduced.
SF 5 -containing drugs
Pentafluorosulfanyl (-SF 5 ) is a potential replacement for trifluoromethyl (-CF 3 ) and with easier access to synthetic building blocks, such as SF 5 -nitrobenzene, several drug analogs have been synthesized containing this functional group (Fig. 10) , such as the antimalarial agent mefloquine and the SSRI blockbuster drug fluoxetine (Prozac) (Welch and Lim 2007; Mo et al. 2010) . The substantial interest in drug molecules bearing the SF 5 moiety derives from its greater electronegativity (3.65 vs 3.36 for CF 3 ) and the improvement in stability and hydrophobicity of molecules bearing this substituent in comparison to those with a trifluoromethyl group (Bowden et al. 2000; Reddy 2015; Sheppard 1962) . With the potentially large number of molecules of this type that might be applied as drugs and agrochemicals, it is crucial that the impacts on the Fig. 9 The structure of the anticancer drug flutamide were photolytically labile and released fluoride when exposed to actinic light; however, they were stable when kept in the dark. Kavanagh et al. (2014) demonstrated that SF 5 -substituted anilines could be biotransformed by some bacteria and a fungus to the N-acetyl derivatives, and demonstrated that in Streptomyces griseus, an N-acetyl transferase catalyzed the reaction.
Outlook
Fluorine is an important element in the pharmaceutical industry, and as synthetic methods are developed to make fluorinated compounds more easily, for example, using continuous flow methods with fluorine gas (McPake and Sandford 2012), the number and diversity of fluorinated drugs will increase. In this context, microorganisms may provide important alternatives to chemical catalysis, either through direct C-F bond formation, via fluorinase enzymes, or through the introduction of fluorinated building blocks into complex natural products O'Connor et al. 2014; O'Hagan and Deng 2015) . Furthermore, microorganisms can help direct fluorine incorporation into drug compounds to improve their metabolic stability (Shaughnessy et al. 2014) . While fluorine can convey useful properties to drugs, the stability of the C-F bond often makes these compounds recalcitrant. Once released into the environment, through wastewater, sludge, and directly from farm animals, fluorinated drugs C. elegans X X X X X X X X X X X X X SF5-fluoxetine SF5-mefloquine Fig. 10 Structures of pentafluorosulfanyl derivatives of the drugs fluoxetine and mefloquine will encounter microorganisms. The microorganisms might be inhibited by the drug, evolve resistance (if it is an antibiotic), or biotransform it, potentially to a more toxic compound. It is clear from a review of the literature that only a small portion of the available fluorinated drugs currently in use have been investigated with respect to their biodegradation and that complete mineralization of any fluorinated drug, by either an isolated microorganism or in a mixed culture, is rare. A handful of enzymes have been identified thus far that will biotransform fluorinated drugs; thus, much work remains to identify others. Should this area of research be ignored and effective remediation solutions are not developed, of which microorganisms would likely play a part, there is a risk that regulatory authorities will impose restrictions on the use of the drugs. In particular, this applies to widely prescribed drugs such as fluoxetine, which are not eliminated by conventional waste water treatment and are known to have an impact on aquatic life. The development of pharmaceuticals with new fluorinated substituents is exciting, but brings with it additional challenges with respect to the eventual fate of the compounds and their broader environmental effects. On the other hand, a greater understanding of microbial biotransformation will also enable the discovery of novel enzyme activities that may have potential as industrial biocatalysts for the production of new fluorinated compounds.
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